Cargando…

Third generation autologous chondrocyte implantation is a good treatment option for athletic persons

PURPOSE: Autologous chondrocyte implantation is an established method for the treatment of joint cartilage damage. However, to date it has not been established that autologous chondrocyte implantation is an appropriate procedure for cartilage defects therapy in athletic persons. The aim of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Niethammer, Thomas Richard, Altmann, Daniel, Holzgruber, Martin, Goller, Sophia, Fischer, Andreas, Müller, Peter Ernst
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973642/
https://www.ncbi.nlm.nih.gov/pubmed/32671436
http://dx.doi.org/10.1007/s00167-020-06148-5
_version_ 1783666875145650176
author Niethammer, Thomas Richard
Altmann, Daniel
Holzgruber, Martin
Goller, Sophia
Fischer, Andreas
Müller, Peter Ernst
author_facet Niethammer, Thomas Richard
Altmann, Daniel
Holzgruber, Martin
Goller, Sophia
Fischer, Andreas
Müller, Peter Ernst
author_sort Niethammer, Thomas Richard
collection PubMed
description PURPOSE: Autologous chondrocyte implantation is an established method for the treatment of joint cartilage damage. However, to date it has not been established that autologous chondrocyte implantation is an appropriate procedure for cartilage defects therapy in athletic persons. The aim of this study is to analyze if third-generation autologous chondrocyte implantation is an appropriate treatment for athletic persons with full cartilage defect of the knee joints. METHODS: A total of 84 patients were treated with third-generation autologous chondrocyte implantation (NOVOCART(®) 3D). The mean follow-up time was 8 years (5–14). Sports activity was measured via UCLA Activity Score and Tegner Activity Scale before the onset of knee pain and postoperatively in an annual clinical evaluation. 41 athletic persons and 43 non-athletic persons (UCLA-Cut-off: 7; Tegner Activity Scale-Cut-off: 4) were analyzed. Patient reported outcomes were captured using IKDC subjective, KOOS, Lysholm score and VAS score on movement. RESULTS: Patient reported outcomes (IKDC, VAS at rest, VAS on movement) showed significant improvement (p < 0.001) postoperatively. Athletic persons demonstrated significantly better results than non-athletic persons in the analyzed outcome scores (IKDC: p < 0.01, KOOS: p < 0.01, Lysholm score: p < 0.01). 96.4% of the patients were able to return to sport and over 50% returned or surpassed their preinjury sports level. The remaining patients were downgraded by a median of two points on the UCLA- and 2.5 on the Tegner Activity Scale. A shift from high-impact sports to active events and moderate or mild activities was found. Furthermore, it was shown that preoperative UCLA score and Tegner Activity Scale correlated significantly with the patient reported outcome postoperatively. CONCLUSION: Autologous chondrocyte implantation is a suitable treatment option for athletic persons with full-thickness cartilage defects in the knee. The return to sports activity is possible, but includes a shift from high-impact sports to less strenuous activities.
format Online
Article
Text
id pubmed-7973642
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-79736422021-04-05 Third generation autologous chondrocyte implantation is a good treatment option for athletic persons Niethammer, Thomas Richard Altmann, Daniel Holzgruber, Martin Goller, Sophia Fischer, Andreas Müller, Peter Ernst Knee Surg Sports Traumatol Arthrosc Knee PURPOSE: Autologous chondrocyte implantation is an established method for the treatment of joint cartilage damage. However, to date it has not been established that autologous chondrocyte implantation is an appropriate procedure for cartilage defects therapy in athletic persons. The aim of this study is to analyze if third-generation autologous chondrocyte implantation is an appropriate treatment for athletic persons with full cartilage defect of the knee joints. METHODS: A total of 84 patients were treated with third-generation autologous chondrocyte implantation (NOVOCART(®) 3D). The mean follow-up time was 8 years (5–14). Sports activity was measured via UCLA Activity Score and Tegner Activity Scale before the onset of knee pain and postoperatively in an annual clinical evaluation. 41 athletic persons and 43 non-athletic persons (UCLA-Cut-off: 7; Tegner Activity Scale-Cut-off: 4) were analyzed. Patient reported outcomes were captured using IKDC subjective, KOOS, Lysholm score and VAS score on movement. RESULTS: Patient reported outcomes (IKDC, VAS at rest, VAS on movement) showed significant improvement (p < 0.001) postoperatively. Athletic persons demonstrated significantly better results than non-athletic persons in the analyzed outcome scores (IKDC: p < 0.01, KOOS: p < 0.01, Lysholm score: p < 0.01). 96.4% of the patients were able to return to sport and over 50% returned or surpassed their preinjury sports level. The remaining patients were downgraded by a median of two points on the UCLA- and 2.5 on the Tegner Activity Scale. A shift from high-impact sports to active events and moderate or mild activities was found. Furthermore, it was shown that preoperative UCLA score and Tegner Activity Scale correlated significantly with the patient reported outcome postoperatively. CONCLUSION: Autologous chondrocyte implantation is a suitable treatment option for athletic persons with full-thickness cartilage defects in the knee. The return to sports activity is possible, but includes a shift from high-impact sports to less strenuous activities. Springer Berlin Heidelberg 2020-07-15 2021 /pmc/articles/PMC7973642/ /pubmed/32671436 http://dx.doi.org/10.1007/s00167-020-06148-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Knee
Niethammer, Thomas Richard
Altmann, Daniel
Holzgruber, Martin
Goller, Sophia
Fischer, Andreas
Müller, Peter Ernst
Third generation autologous chondrocyte implantation is a good treatment option for athletic persons
title Third generation autologous chondrocyte implantation is a good treatment option for athletic persons
title_full Third generation autologous chondrocyte implantation is a good treatment option for athletic persons
title_fullStr Third generation autologous chondrocyte implantation is a good treatment option for athletic persons
title_full_unstemmed Third generation autologous chondrocyte implantation is a good treatment option for athletic persons
title_short Third generation autologous chondrocyte implantation is a good treatment option for athletic persons
title_sort third generation autologous chondrocyte implantation is a good treatment option for athletic persons
topic Knee
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973642/
https://www.ncbi.nlm.nih.gov/pubmed/32671436
http://dx.doi.org/10.1007/s00167-020-06148-5
work_keys_str_mv AT niethammerthomasrichard thirdgenerationautologouschondrocyteimplantationisagoodtreatmentoptionforathleticpersons
AT altmanndaniel thirdgenerationautologouschondrocyteimplantationisagoodtreatmentoptionforathleticpersons
AT holzgrubermartin thirdgenerationautologouschondrocyteimplantationisagoodtreatmentoptionforathleticpersons
AT gollersophia thirdgenerationautologouschondrocyteimplantationisagoodtreatmentoptionforathleticpersons
AT fischerandreas thirdgenerationautologouschondrocyteimplantationisagoodtreatmentoptionforathleticpersons
AT mullerpeterernst thirdgenerationautologouschondrocyteimplantationisagoodtreatmentoptionforathleticpersons